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Background: Chronic hepatitis B (CHB) infection during pregnancy is associated with insulin resistance. A
meta-analytic technique was used to quantify the evidence of an association between CHB infection and the
risk of gestational diabetes (GDM) among pregnant women.
Methods: We searched PubMed for studies up to September 5th 2013. Additional studies were obtained from
other sources. We selected studies using a cohort-study design and reported a quantitative association between
CHB infection during pregnancy and risk of GDM. A total of 280 articles were identified, of which fourteen publications
involving 439,514 subjects met the inclusion criteria. A sequential algorithm was used to reduce between-study
heterogeneity, and further meta-analysis was conducted using a random-effects model.
Results: Ten out of the fourteen studies were highly homogeneous, indicating an association of 1.11 [the adjusted
odds ratio, 95% confidence interval 0.96 - 1.28] between CHB infection during pregnancy and the risk of developing
GDM. The heterogeneity of the additional four studies may be due to selection bias or possible aetiological differences
for special subsets of pregnant women.
Conclusions: These results indicate that CHB infection during pregnancy is not associated with an increased risk of
developing GDM among pregnant women except those from Iran.
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The hepatitis B virus (HBV) accounts for significant
morbidity and mortality worldwide [1]. An estimated
one-third of the worldwide population has been exposed
to HBV, and 400 million people are chronic carriers [1].
HBV can be transmitted vertically, sexually, and through
other routes, and pregnant women play important roles
in each of those transmission routes. Chronic hepatitis B
(CHB) infection during pregnancy often results in hep-
atic flare [2] and possibly other adverse outcomes
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GDM is defined as glucose intolerance with an onset
or first recognition during pregnancy. Asian women, in-
cluding Chinese women, have been found to have the
highest incidence of GDM [18]. Women with GDM are
at an increased risk for adverse perinatal and maternal
outcomes including macrosomia, caesarean section,
birth trauma, and diabetes later in life, although treat-
ment significantly decreases these risks [19]. Until now,
liver disease of various aetiologies has been implicated
as a cause of diabetes [20], and chronic hepatitis C virus
(CHC) infection has been established to increase the risk
of diabetes mellitus (DM) [21].
Similarly to CHC infection, CHB infection is consid-
ered to be associated with insulin resistance (IR) [22],
which implies that it may increase the risk of developingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CHB infection and the risk of DM and/or GDM remains
less convincing. An increased risk was reported for DM
only by Li-Ng [23], but this result was not confirmed by
a recently published ten-year cohort study [24]. Several
studied have reported an increased risk for GDM
[4,6,7,10,11], but this result was contradicted by many
others [3,5,8,9,12-17]. Due to the limited resources and
time available for HBV vaccination, the prevalence of
CHB infection among pregnant women remains high,
especially in HBV epidemic areas such as China [25].
To address these issues, we performed a meta-analysis
of cohort studies to investigate whether CHB infection
during pregnancy is associated with an increased risk
of GDM.
Methods
Data sources and search strategy
This meta-analysis was conducted in compliance with
the Meta-Analysis of Observational Studies in Epidemi-
ology guidelines (http://edmgr.ovid.com/ong/accounts/
moose.pdf). Two independent investigators (Kong and
Liu) searched PubMed from 1966 to September 5th,
2013 using the combinations of terms “hepatitis B” or
“hepatitis B surface antigen (HBsAg)” and “pregnancy
outcome” or “prenatal outcome” or “perinatal outcome”
or “gestational diabetes”. We sifted through potentially
relevant articles, firstly by titles and abstracts, and then
we retrieved the full texts of articles for detailed review.
Further, we scanned the reference lists of the articles
that met the inclusion criteria in our analysis, and
searched for those articles or citations in the Web of
Knowledge, Google Scholar and Google to obtain
additional studies.
Inclusion and exclusion criteria
Articles were included if they used a cohort design and
reported a quantitative association between CHB infec-
tion during pregnancy and the risk of GDM among
pregnant women versus a non-CHB control group. For
studies that enrolled overlapping pregnant women, only
more recently published studies and/or those with larger
sample sizes were included.
Studies included in this analysis defined CHB infection
status during pregnancy by the presence or absence of
hepatitis B surface antigen (HBsAg) in blood during the
first prenatal care visit, on admission to the labour ward,
or before delivery. GDM diagnosis was performed ac-
cording to the recommended clinical practice.
Data extraction
A form designed a priori was used to extract the informa-
tion from the included studies. Two independent investi-
gators (Han and Wei) performed the data extraction. Athird investigator (Wang) examined the results, and a con-
sensus was considered as agreement between at least two
out of the three investigators. GDM was the primary out-
come measure. We extracted the following data (Table 1):
authors’ name, journal and year of publication, country
of origin, enrolment period, incidence of GDM in preg-
nant women who had CHB infection and those who did
not, general characteristics of pregnant women, un-
adjusted and/or adjusted effect size and the adjusted
variables if available.
Assessment of methodological quality
Two independent investigators (Kong and Hu) evaluated
the quality of each study using the Newcastle-Ottawa
Quality Assessment Scale (NOS) [26]. The third investi-
gator (Lu) examined the results, and a consensus was
considered as agreement between at least two out of the
three investigators (Table 1). We did not consider the
2nd item of the NOS scale (Was follow-up long enough
for outcomes to occur) or the 3rd item (Adequacy of fol-
low up of cohort) because the final outcomes of all preg-
nant women were followed up to their delivery dates.
We defined studies with NOS ≥ 7 as high quality and
those with NOS < 7 as low quality.
Statistical analysis
Effect measurement: odds ratio and its adjustment
The cross-study effect of CHB infection vs. non-CHB
control on the risk of GDM was measured using the
odds ratios (OR) with 95% confidence intervals (CIs),
which were reported as the effect measurements in all of
the included studies except for one [4], which reported
relative risk.
The adjusted OR (ORa) was automatically included in
our analysis; the unadjusted or crude OR (ORc) was
corrected using external estimates of confounding by
the method of coefficient adjustment introduced by
Greenland [27]. Briefly, the confounding effect U = ORc/
ORa was calculated by an external study. The variance of
U was estimated using the formula Vu = Va-Vc, where Va
and Vc are the variances of the natural logarithm of the
ORc and ORa from the same study, respectively. Then,
we used U and its variance Vu for further correction. In
our analysis, the ORc from the Lobstein study [12] and
the Chinese or Thailand studies [3,5,8,9,15-17] were
adjusted using the estimates of U and Vu from Reddick
2011 [13] and Lao 2007 [7], respectively.
Heterogeneity analysis and its sensitivity analysis
We used a random-effects model to pool the ORa
across studies in Stata version 10.0 (Stata Corp). Het-
erogeneity was first explored by a χ2 test with a P
value <0.10 considered statistically significant and
then judged visually by a forest plot, funnel plot and
Table 1 General characteristics and quality scores of the 14 studies included in this meta-analysis
No Author, publication year, design (matched
variables), study site, country, PW (no,










1. Wong SF, 1999 PW delivered after 24 GW or babies
with BW ≥ 500 g/AHP, non-SP, acute
pelvic inflammatory disease, STI,







NA ORc = 1.05 (0.69, 1.61)






2. Lao TT, 2003
Chinese PW, recruited at 28-30 GW,
haemoglobin concentration ≥10 g/dl
and mean cell volume ≥ 80 fL at the initial
visit at or before 14 GW/antenatal visit
after 14 GW, anemia or hemoglobinopathy,















history and had an
advanced age
(≥35 years)
RRc = 2.97 (2.00, 4.42)
RCS, with a sample as controls ORc = 3.94 (2.27, 6.84)
Queen Mary Hospital or others RRa = 3.51
(1.83, 6.73)/Age, BMI,
socioeconomic status,





Over four months (5)
3. To WWK, 2003 PW delivered after 24 GW/AHP(2);





Age, GW at delivery,
BMI, parity, incidence
of non-SP or STIs; no
clinical manifestations
of liver disorders or
hepatitis.
A higher prop. of
HBsAg + PW from
mainland China
ORc = 0.81 (0.59, 1.12 )





Jan. 1997-Dec. 2000 (6)
4. Tse KY, 2005 NA/incomplete data ELISA/WHO
criteria (medical
record)
BMI, height, weight and
Hb level at booking, ethnic,
history of stillbirth, IVF
pregnancy, haemoglobin
level at booking, past
medical history
Among the HBsAg +
PW, the weight gain in
those with GDM was
significant less than
those without GDM.
ORc = 1.89 (1.14, 3.13)
RCS, matched for age and parity ORa = 2.04 (1.21, 3.44)/Age,
weight and parity
Queen Mary Hospital (section mainly for
high-risk paturients)
Hongkong, China
SP (3348, 7.56%) Among the HBsAg-
PW, the weight gain in





5. Lao TT, 2007 SP, 99% of those PW delivered at or after




Age, height, parity and
history of DM
The HBsAg + PW had
lower weight and BMI,
with lower prop. of
overweight and
ORc = 1.31(1.08, 1.57)
RCS, with all HBsAg- as controls ORa = 1.24 (1.01, 1.51)/


































6. Lert-amornpong S,2007 Healthy PW Age 20-39 years old/chronic ill-
ness, non-SP, HIV+, smoker, alcohol drinker
ELISA/NDDG
(medical record)
Age, weight at booking,




NA ORc = 3.04 (0.60, 15.28)
RCS, matched for age and date of delivery ORa = 2.89 (0.55, 15.17)
*1/NA




7. Thungsuk R, 2008 Healthy PW ELISA/ADA
(medical record)
Age, hematocrit at
booking, parity and past
health
NA ORc = 1.39 (0.37, 5.28)
RCS, matched for age, parity and year of
delivery
Age 20-39 years old/chronic illness, non-SP,
HIV+, smoker, alcohol drinker





Jan. 2005-Dec, 2007 (5)






NA ORc = 4.13 (1.96, 8.70)
RCS, matched for age, parity, and BMI ORa = 3.62 (1.60, 7.90)/NA




Mar. 2001-Dec. 2008 (6)
9. Aghamohammadi A, 2011 SP/ ELISA/ADA
(medical record)
Age, parity, haemoglobin
level at booking, past
medical history
NA ORc = 2.34 (1.32, 4.17)
RCS, matched for age and parity, selected at
random
AHP ORa = 1.53 (1.19, 1.97)/NA













The HBsAg + PW had
lower weight and
height, higher prop. of
Asian origin, married,
unemployed, history of
ORc = 2.82 (0.17, 46.68)



























Jan 1, 2001-Dec. 31,2006 (6)
11. Reddick KL, 2011 NA/DM, HCV ELISA/ADA NA The HBsAg + PW were
younger, with more
black and Asian, and
higher prop. of public-
assisted insurance, any
substance use, any STI
and medical
complications
ORc = 1.78 (1.27, 2.50)
RCS, with all HBsAg- as controls ORa = 1.39 (0.88, 2.12)/age,
race, insurance status,






12. Lu YP, 2012 SP/pre-existing diabetes, impaired glucose
tolerance, hypertension, etc; syphilis, HIV;
co-infected or super-infected with HCV, HDV,
HAV, HEV and other infections, smokers drug
users, alcohol drinkers and prescription users.
ELISA/ADA
(medical record)
Age, height, BMI before
pregnancy, parity, times of
pregnancy, GW
NA ORc = 0.90 (0.48, 1.67)
RCS, with a random sample of all HBsAg- as
controls
ORa = 0.85 (0.41, 1.77)
*1/NA
First Affiliated Hospital of Jinan University
Guangzhou,,China
SP (NA, NA)
May 2009-Jul. 2011 (6)





Height and medical history The HBsAg + PM were
insignificantly younger,
and with higher prop.
of overweight, BMI
and multiple parity
ORc = 0.96 (0.88, 1.04)
RCS, with all HBsAg- as controls ORa = 0.91 (0.62, 1.34)
*1/NA
Princess of Wales Hospital
Hongkong, China
SP (86537, 10.0%)
Jan. 1995-Dec. 2009 (5)






Parity was higher in
HBsAg + PW
ORc = 0.97 (0.74, 1.28)





Oct. 1st, 2010- Dec. 31st, 2011 (6)
Notes.
PW: pregnant women; NOS: Newcastle-Ottawa Quality Assessment Scale; no: number; HBsAg: hepatitis B virus surface antigen; GDM: gestational diabetes mellitus; CI: confidence interval; RCS: retrospective cohort study;
SP: single pregnancy; GW: gestational weeks; BW: birth weight; AHP: acute hepatitis during pregnancy; STI: sexually transmitted infection; DM: diabetes mellitus; ELISA: Enzyme-linked immunosorbent assay; NA: not
available; ORc: crude odds ratio; ORa: adjusted odds ratio; WHO: World Health Organization; BMI: body mass index; OGTT: oral glucose tolerance test; RRc: crude risk ratio; RRa: adjusted risk ratio; Hb: haemoglobin;
IVF: In vitro fertilization; prop: proportion; HIV: human immunodeficiency virus; NDDG: National Diabetes Data Group; ADA: American Diabetes Association; IADPSG: International Association of Diabetes in Pregnancy
Study Group; HCV: hepatitis C virus; HDV: hepatitis D virus; HAV: hepatitis A virus; HEV: hepatitis E virus; ICD: International Classification of Diseases.
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http://www.biomedcentral.com/1756-0500/7/139Galbraith plot. The extent of heterogeneity was mea-
sured by Higgins’ I2. We also explored the influence of
heterogeneity on the pooled ORa across studies using
a sensitivity analysis introduced by Patsopoulos [28].
Briefly, for a meta-analysis of n studies, we perform n
new meta-analyses where one study is excluded from
the calculation each time. The study that leads to the
largest decrease in I2 upon exclusion is dropped, and a
new set of n-1 studies is created. This process is
continued until the I2 is decreased to the lowest pos-
sible value.
For the heterogeneous studies that were excluded from
further analysis, we explored the possible reasons for the
heterogeneity using a causal diagram.
The combined effect estimate
For the homogenous studies, the Dersimonian and Laird
random-effects model was used to pool the ORa across
studies in Stata version 10.0 (Stata Corp). Sub-group
analysis and meta-regression were carried out to exam-
ine the effect in relation to design, type of epidemic area,
article quality and GDM diagnostic criteria. We used the
interaction test to estimate the difference between two
sub-groups [29]. Publication bias was assessed by a vis-
ual inspection of a funnel plot and by the Egger’s and
Begger’s test [30], and a nonparametric trim and fill
method was applied if possible [31]. The predictive in-
tervals were calculated using a t-distribution with k-2




The literature search retrieved 280 papers, 29 of which
were identified as potentially relevant to the current
analysis. Further backwards or citation searches pro-
duced six additional papers. Only fourteen papers
[3-13,15-17] representing fourteen independent stud-
ies were included in our analysis. The reasons for
exclusion of the other studies are listed in Additional
file 1: Figure S1.General characteristics about the studies included in
meta analysis
The fourteen studies included in the present analysis
were published between 1999 and 2013 (Table 1). Two
studies each were conducted in Thailand [8,9] and Iran
[10,11], one in Germany [12], the United States [13], and
mainland China [15], and the other seven in Hong Kong,
China [3-7,16,17]. All fourteen were hospital-based
retrospective cohort studies.
The CHB infection status was determined by the pres-
ence or absence of HBsAg during pregnancy, and thediagnosis of GDM was determined through routine
clinical practices. This information was retrieved dir-
ectly from medical records or indirectly from medical
records based on a computerised database through the
International Classification of Diseases codes.
Heterogeneity analysis and its sensitivity analysis
The high heterogeneity of the ORa across the fourteen
studies was demonstrated by visual observation of the
forest plot, funnel plot, and Galbraith plot and further
verified by the Higgins’ I2 value of 58.9% (χ2 = 31.6,
df = 13, p = 0.003).
I2 was reduced by removing one study at a time using
a random-effects model based sequential algorithm [28].
As seen from Figure 1a-d, removing one study each time
led to a gradual decrease in the Tau-squared value with
decreasing I2, and the 95% CIs of the pooled ORa across
studies became narrower, with the means, lower and
upper 95% CIs ranging from 1.00 - 1.40, 0.82 - 1.13, and
1.21 - 1.78, respectively. Actually, 38% of the 95% lower
CIs were below 1.0 during this process.
After four studies were removed (Lao 2003 [4], Saleh-
Gargari 2009 [10], Tse 2003 [6] and Aghamohammadi
2011 [11]), the remaining ten studies were highly homo-
geneous, with a Higgins’ I2 value of 0.0% (χ2 = 8.06,
df = 9, p = 0.53, Figure 2) and a Tau-squared value of 0.0.
The combined effect estimate
The ten highly homogeneous studies involved 99.4%
(436,991/439,514) of the subjects among the fourteen
studies, and together reported a GDM prevalence of
6.30% (884/14,028) among pregnant women with CHB
infections and 3.63% (15,352/422,963) among uninfected
pregnant women. The association between CHB infec-
tion during pregnancy and the risk of developing GDM
was 1.11 [the adjusted odds ratio (ORa), 95% CIs: 0.96 -
1.28, 95% predictive intervals 0.94 - 1.31] (Figure 2).
These findings suggest that CHB infection during preg-
nancy does not increase the risk of GDM, in agreement
with all of the individual studies except for one [7],
which suggests that CHB infection during pregnancy is
associated with a higher risk of GDM.
Subgroup and meta-regression analysis showed that
the pooled ORa across studies could not be modified by
the following characteristics: quality of papers (high vs.
low), designs (all non-CHB pregnant women as controls
vs. an unmatched or matched sample of non-CHB preg-
nant women as controls), epidemic levels (high, middle
vs. low), and GDM diagnostic criteria.
Visual inspection of the funnel plots of the ORa from
the ten studies demonstrated a possible publication bias.
After trim and fill methods were performed, the pooled
ORa was 1.10 (95% CIs: 0.96 - 1.26; 95% predictive inter-
vals: 0.94 - 1.30) (Figure 3).
Step 1: Lao 2003
Step 2: Saleh-Gargari 2009
Step 3: Tse 2005





Figure 1 Pooled odds ratios, their 95% confidence intervals, Tau-squared and Higgins’ I2 values for the association between chronic
hepatitis B infection during pregnancy and the occurrence of gestational diabetes mellitus using a random-effects model based
sequential algorithm. OR: odds ratio; ORL: 95% lower confidence limit of OR; ORH: 95% higher confidence limit of OR; Notes: In each step of
the analysis, one study was removed out of: (a) the original fourteen studies (Step 1); (b) the remaining thirteen studies after the exclusion of the
Lao 2003 (Step 2); (c) the remaining twelve studies after the exclusion of Lao 2003 and Saleh-Gargari 2009 (Step 3); (d) the remaining eleven studies
after the exclusion of Lao 2003, Saleh-Gargari 2009 and Tse 2003 (Step 4). The arrows point to the studies whose removal minimises the
Higgins’ I2 value. The blue, green and orange hollow circles denote the pooled ORa, 95% ORL and ORH, respectively, and the red multiple
signs denote the Tau-squared values.
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http://www.biomedcentral.com/1756-0500/7/139Possible reasons for the heterogeneity of the remaining
four studies
The four heterogeneous studies that were excluded from
further analysis all reported a higher risk of GDM for
pregnant women with CHB infection (Figure 2). The ef-
fect of their removal on the heterogeneity was depictedwithin a causal diagram (Figure 4). The first and third
excluded studies, Lao 2003 [4] and Tse 2003 [6], respect-
ively, had both recruited a special subset of pregnant
women from the population in Hong Kong, China. For
the former study, CHB infected pregnant women were
subjected to more rigorous oral glucose tolerance testing
NOTE: Weights are from random effects analysis
OR (95% CI) Weight%
favoring Control  favoring CHB
Overall  (I−squared = 0.0%, p = 0.528) 1.11 (0.96, 1.28) 100.0015489/4245631025/14951
2 3 4 5.1 10 201
1.00 (0.57, 1.77) 6.04Wong SF 1999 25/824 181/6281
Hongkong, China
0.77 (0.47, 1.26) 7.95To WWK 2003 478/1245242/1340
Hongkong, China
Lao TT 0.91 (0.62, 1.34) 13.012013 5222/77936553/8636
Hongkong, China
1.24 (1.01, 1.52) 48.34Lao TT 2007 1227/12547141/1138
Hongkong, China
0.92 (0.58, 1.48) 8.922013 710/877859/748Mak SL
Hongkong, China
2.89 (0.55, 15.17) 0.71Lert-Amornpong S 2007 2/1626/164
Bangkok, Thailand
1.32 (0.33, 5.29) 1.02Thungsuk  R 2008 4/1705/154
Nakhonsawan, Thailand
2.20 (0.13, 37.02) 0.25Lobstein S 2011 36/81540/39
Leipizig, Germany
1.39 (0.90, 2.16) 10.11Reddick KL 2011 7464/29621835/797
37 states, USA






No of GDM / No of Total
CHB non-CHB
2.04 (1.21, 3.44) R3Tse KY 2005 28/25348/253
Hongkong, China
3.32 (1.72, 6.41) R1Lao TT 2003 77/69723/70
Hongkong, China
3.62 (1.63, 8.04) R2Saleh-Gargari S 2009 9/45035/450
Tehran, Iran
1.53 (1.19, 1.97) R4Aghamohammadi A 2011 23/20035/150
Sari, Iran
with predictive intervals  (0.94, 1.31)
Figure 2 Effect of chronic hepatitis B infection during pregnancy on the occurrence of gestational diabetes mellitus using a random-effects
model. OR: odds ratio; CI: confidence interval; CHB: chronic hepatitis B infection; GDM: gestational diabetes mellitus. Notes: The black boxes
denote the ten studies used for this analysis; the hollow boxes with the same size denote the four studies that were excluded from the analysis.
R1, R2, R3 and R4 denote the studies in the order of their removal during the process for the reduction of Higgins’ I2.
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http://www.biomedcentral.com/1756-0500/7/139(OGTT), and exhibited a higher serum ferritin concen-
tration which was considered to be both an outcome of
the CHB infection and a risk factor of GDM [33]. The
pregnant women in the latter study had multiple risk
factors, with some suffering from significant medical dis-
eases requiring active treatment, including pre-existing
diabetes mellitus. Both CHB infection during pregnancy
and GDM may lead to a high-risk status among preg-
nant women, which would affect their recruitment into
the study. Thus, both studies may have enrolled more
CHB infection-related GDM [34], a selection bias result-
ing in the overestimation of the association between CHB
infection and GDM. The second and fourth excluded
studies, Saleh-Gargari 2009 [10] and Aghamohammadi
2009 [11], respectively, were both conducted in Iran with
similar designs. As we know, the prevalence of both CHB
infection and GDM differs among ethnic groups [18],
making it possible that the CHB infection-GDM asso-
ciation may exist in pregnant Iranian women but not
the others. These issues should be addressed further
in future studies.Discussion
Our results suggest that CHB infection during preg-
nancy does not represent a significant general risk for
the development of GDM as compared to non-CHB in-
fected controls.
The high initial between-study heterogeneity in this
meta-analysis prevented us from drawing strong con-
clusions. To overcome this problem, we firstly used a
sequential algorithm based sensitivity analysis of between-
study heterogeneity [28], which differentiated those
homogenous studies from the other heterogeneous
ones. This strategy was helpful in identifying and se-
quentially excluding the heterogeneous studies, i.e., at
least those with outliers, which made the analysis
based on the random-effects model more reasonable
[32]. Although the acceptable level of heterogeneity
remains unknown [35], we were conservative and
chose the lowest Higgins’ I2 as our standard for this
differentiation. As a result, this strategy resulted in a
parallel decrease in both Higgins’ I2 and Tau-squared,






Standard error of Ln (OR)






Figure 3 The Egger’s funnel plot with pseudo 95% confidence limits for the ten homogenous studies analysing the effect of chronic
hepatitis B infection during pregnancy on the occurrence of gestational diabetes mellitus by using trim and filled methods. OR: odds
ratio; Ln: natural logarithm. The hollow circles with or without enclosed boxes represented the original and filled studies, respectively.
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http://www.biomedcentral.com/1756-0500/7/139Finally, we differentiated ten homogenous studies
from the remaining four heterogeneous ones.
Those ten homogeneous studies reported GDM preva-
lences of 6.30% and 3.63% among pregnant women with
and without CHB infection, respectively. The risk of
GDM for CHB-infected pregnant women was compar-
able to the risk for uninfected women (ORa = 1.11, 95%
CI: 0.96-1.28). These findings suggest that CHB infection
during pregnancy is not associated with an additional
risk of GDM.
Two of the heterogeneous studies, Lao 2003 [4] and
Tse 2003 [6], provided further support. The study of Lao
2003 [4] enrolled pregnant women with higher levels of







Figure 4 Possible causal diagram related to the four excluded studies
during pregnancy and gestational diabetes mellitus. CHB: chronic hep
The arrow represents a causal relationship between the two variables at bo
the outcome of the variable at the other end of the arrow. The red arrow d
other variables that could affect this relationship. The author names and puadvanced fibrosis of non-alcoholic fatty liver disease
[36]. The study of Tse 2003 [6] enrolled high-risk preg-
nant women. Thus, both of these studies may have en-
rolled women with more progressive stages of CHB
infection, which would have resulted in the overestimation
of the association between CHB infection and GDM.
It remains unclear why only Iranian pregnant women
with CHB infection appear to have an increased risk of
GDM. Both Iranian studies, Saleh-Gargari 2009 [10] and
Aghamohammadi 2011 [11], were conducted on Iranian
pregnant women with similar designs [10,11] but reported
a significantly higher association between CHB infection
and GDM than the other studies analysed here. Since the
occurrence of both CHB infection and GDM differsPop. recruited
Tse 2003
analysing the relationship between chronic hepatitis B infection
atitis B infection; GDM: gestational diabetes mellitus; Pop: population.
th edges of the arrow. The variable that the arrow points to denotes
enotes the relationship under study. The blue arrow lines denote the
blication years are associated with the variables as appropriate.
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ence in the association between CHB infection and GDM.
GDM is characterised by pancreatic β-cell dysfunction
that results in insulin resistance (IR). IR has been shown
to be associated with both CHC and CHB infection [22],
but CHC related IR was mainly due to steatosis develop-
ment [37] or fibrosis progression [38], which seems to
be insignificant for CHB infection as most pregnant
women with CHB infections are asymptomatic or ex-
periencing mild hepatic injury [39].
Routine screening for GDM is recommended near the
beginning of the third trimester, and the identification of
GDM will depend on the diagnostic criteria and guide-
lines. For economic, psychological and other reasons,
GDM screening is conducted using a risk factor-based
selective screening approach in most countries rather
than universal screening. These differences in strategies
did not seem to affect the non-significant association be-
tween CHB infection and the risk of GDM [12-14,16,17],
which was further supported by our sub-group and
meta-regression analysis. Only one out of the ten
homogenous studies reported a positive association be-
tween CHB infection and the risk of GDM [7]. This
difference can be explained by the fact that the replace-
ment of the Australian standard for GDM diagnosis with
the WHO standard would have resulted in the inclusion
of individuals with impaired glucose tolerance into the
GDM group. Routinely, pregnant women will receive the
same screening and are subjected to the same diagnostic
criteria in the same study regardless of CHB infection
status, so issues of this type seem to play insignificant
roles in most of the studies [3,5,8,9,13,14,16,17]. Future
studies should use a universal screening strategy together
with the new diagnostic criteria established for GDM.
Conclusions
Our findings imply that GDM is not attributable to CHB
infection during pregnancy. Thus, any extra GDM
screening for this population is not necessary, which is a
commonly accepted practice throughout the world ex-
cept in Hong Kong, China. This extra screening will
likely result in a greater economic burden and additional
psychological concerns such as fear or guilt, especially in
epidemic areas, like China. Probably, advanced clinical
stages of liver diseases of varied aetiologies may be more
important in the development of GDM, and the signifi-
cantly high association between CHB infection and
GDM in Iranian pregnant women is worth further study.
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